FDA Clears Rheumatoid Dx Test by Bio-Rad, Axis-Shield | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories and Axis-Shield today announced the US Food and Drug Administration has cleared Bio-Rad's BioPlex 2200 Anti-CCP test for the early detection of rheumatoid arthritis.

The test, which is based on Axis-Shield's proprietary anti-CCP technology, is now being launched in the US. The test was made available outside the US earlier this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.